Spots Global Cancer Trial Database for nsclc stage iiib
Every month we try and update this database with for nsclc stage iiib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase 2 Study of Dacomitinib in NSCLC | NCT04027647 | NSCLC Stage III... NSCLC Stage III... NSCLC Stage IV Recurrent NSCLC EGFR Positive N... | Dacomitinib | 18 Years - | National Cancer Centre, Singapore | |
| Phase I Study of SPH1188-11 in NSCLC | NCT03231475 | NSCLC Stage III... NSCLC Stage IV | SPH1188-11 | 18 Years - 70 Years | Shanghai Pharmaceuticals Holding Co., Ltd | |
| Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer | NCT03628144 | Non Small Cell ... NSCLC Non-small Cell ... Non-small Cell ... Non-small Cell ... NSCLC Stage III... NSCLC, Stage II... | Impact® Advance... Boost® High Pro... Radiation Thera... Chemotherapy Quality of life... Evaluation of C... Mindfulness Que... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC | NCT05212922 | HCC NSCLC Stage III... NSCLC Stage IV | YH001 + Toripal... | 18 Years - | Eucure (Beijing) Biopharma Co., Ltd | |
| Phase I Study of SPH1188-11 in NSCLC | NCT03231475 | NSCLC Stage III... NSCLC Stage IV | SPH1188-11 | 18 Years - 70 Years | Shanghai Pharmaceuticals Holding Co., Ltd | |
| Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG) | NCT05281406 | NSCLC Stage III... NSCLC Stage IV | Osimertinib Pemetrexed Cisplatin Carboplatin | 18 Years - | Goethe University | |
| A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC | NCT05212922 | HCC NSCLC Stage III... NSCLC Stage IV | YH001 + Toripal... | 18 Years - | Eucure (Beijing) Biopharma Co., Ltd | |
| 1st Line Durvalumab in PS 2 NSCLC Patients | NCT03620669 | NSCLC Stage IV NSCLC Stage III... | Durvalumab | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors | NCT03647956 | NSCLC Stage III... NSCLC Stage IV EGFR Activating... | Atezolizumab Bevacizumab Carboplatin Pemetrexed | 18 Years - | The University of Hong Kong | |
| Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) | NCT05816499 | NSCLC Stage IV NSCLC Stage III... NSCLC Stage III... | Cadonilimab Anlotinib Docetaxel | 18 Years - | Shanghai Chest Hospital | |
| A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC | NCT05212922 | HCC NSCLC Stage III... NSCLC Stage IV | YH001 + Toripal... | 18 Years - | Eucure (Beijing) Biopharma Co., Ltd | |
| 1st Line Durvalumab in PS 2 NSCLC Patients | NCT03620669 | NSCLC Stage IV NSCLC Stage III... | Durvalumab | 18 Years - | Swiss Group for Clinical Cancer Research | |
| A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies | NCT04042558 | NSCLC Stage III... NSCLC Stage IV EGFR Gene Mutat... ALK Gene Rearra... ROS1 Gene Mutat... | Carboplatin + P... Carboplatin + P... | 18 Years - 75 Years | Centre Francois Baclesse | |
| Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor | NCT04932343 | NSCLC Stage IV NSCLC Stage III... | cohort study | - | Samsung Medical Center | |
| Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients | NCT04223596 | Lung Cancer NSCLC NSCLC Stage III... NSCLC Stage IV | Brigatinib | 18 Years - | Fundación GECP | |
| Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer | NCT03628144 | Non Small Cell ... NSCLC Non-small Cell ... Non-small Cell ... Non-small Cell ... NSCLC Stage III... NSCLC, Stage II... | Impact® Advance... Boost® High Pro... Radiation Thera... Chemotherapy Quality of life... Evaluation of C... Mindfulness Que... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients | NCT04223596 | Lung Cancer NSCLC NSCLC Stage III... NSCLC Stage IV | Brigatinib | 18 Years - | Fundación GECP | |
| Chemoradiotherapy of NSCLC Stage IIIB | NCT00198432 | NSCLC Stage III... Concomitant Rad... | Paclitaxel, vin... | 18 Years - 70 Years | Intergroupe Francophone de Cancerologie Thoracique | |
| Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer | NCT03628144 | Non Small Cell ... NSCLC Non-small Cell ... Non-small Cell ... Non-small Cell ... NSCLC Stage III... NSCLC, Stage II... | Impact® Advance... Boost® High Pro... Radiation Thera... Chemotherapy Quality of life... Evaluation of C... Mindfulness Que... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Exercise in Patients With Advanced Non-small Cell Lung Cancer | NCT06374160 | Advanced Lung C... First Line Trea... Second Line Tre... NSCLC Stage IV NSCLC Stage III... Palliative Trea... NSCLC Stage III... | Exercise interv... | 18 Years - | University Hospital, Essen | |
| A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies | NCT04042558 | NSCLC Stage III... NSCLC Stage IV EGFR Gene Mutat... ALK Gene Rearra... ROS1 Gene Mutat... | Carboplatin + P... Carboplatin + P... | 18 Years - 75 Years | Centre Francois Baclesse | |
| Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG) | NCT05281406 | NSCLC Stage III... NSCLC Stage IV | Osimertinib Pemetrexed Cisplatin Carboplatin | 18 Years - | Goethe University | |
| Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC | NCT04768491 | EGFR Activating... NSCLC Stage IV NSCLC Stage III... NSCLC, Recurren... | Dacomitinib | 18 Years - | Peking Union Medical College | |
| Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor | NCT04932343 | NSCLC Stage IV NSCLC Stage III... | cohort study | - | Samsung Medical Center | |
| Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer | NCT05132218 | ALK Positive NSCLC Stage III... NSCLC Stage IV | Ensatinib | 18 Years - | Peking University Cancer Hospital & Institute | |
| Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) | NCT05816499 | NSCLC Stage IV NSCLC Stage III... NSCLC Stage III... | Cadonilimab Anlotinib Docetaxel | 18 Years - | Shanghai Chest Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
